DE69714591T2 - Prostatakrebs- spezifischer antikörper für immundetektion und immuntherapie - Google Patents
Prostatakrebs- spezifischer antikörper für immundetektion und immuntherapieInfo
- Publication number
- DE69714591T2 DE69714591T2 DE69714591T DE69714591T DE69714591T2 DE 69714591 T2 DE69714591 T2 DE 69714591T2 DE 69714591 T DE69714591 T DE 69714591T DE 69714591 T DE69714591 T DE 69714591T DE 69714591 T2 DE69714591 T2 DE 69714591T2
- Authority
- DE
- Germany
- Prior art keywords
- melanoma
- immunotherapy
- prostate cancer
- specific antibodies
- immune detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/654,641 US5719032A (en) | 1992-01-31 | 1996-05-28 | Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy |
PCT/CA1997/000368 WO1997045744A1 (en) | 1996-05-28 | 1997-05-28 | Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69714591D1 DE69714591D1 (de) | 2002-09-12 |
DE69714591T2 true DE69714591T2 (de) | 2003-04-10 |
Family
ID=24625687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69714591T Expired - Fee Related DE69714591T2 (de) | 1996-05-28 | 1997-05-28 | Prostatakrebs- spezifischer antikörper für immundetektion und immuntherapie |
Country Status (8)
Country | Link |
---|---|
US (1) | US5719032A (de) |
EP (1) | EP0906576B1 (de) |
AT (1) | ATE221996T1 (de) |
AU (1) | AU2883597A (de) |
CA (1) | CA2256310A1 (de) |
DE (1) | DE69714591T2 (de) |
ES (1) | ES2180052T3 (de) |
WO (1) | WO1997045744A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10311248A1 (de) * | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6678669B2 (en) | 1996-02-09 | 2004-01-13 | Adeza Biomedical Corporation | Method for selecting medical and biochemical diagnostic tests using neural network-related applications |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
US5994085A (en) * | 1997-08-26 | 1999-11-30 | Cantor; Thomas L. | Methods and devices for detecting non-complexed prostate specific antigen |
CA2368672A1 (en) * | 1999-03-24 | 2000-09-28 | Genset S.A. | Genomic sequence of the purh gene and purh-related biallelic markers |
KR101637908B1 (ko) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
WO2006086345A2 (en) * | 2005-02-07 | 2006-08-17 | The Trustees Of Columbia University In The City Of New York | Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity |
EP1993606A4 (de) * | 2006-02-15 | 2010-01-20 | Gammacan Ltd | Immunglobuline aus vitiligo-plasma für melanomtherapie |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5605831A (en) * | 1992-01-31 | 1997-02-25 | University Of British Columbia | Human melanoma cell specific antigens and antibodies |
-
1996
- 1996-05-28 US US08/654,641 patent/US5719032A/en not_active Expired - Fee Related
-
1997
- 1997-05-28 EP EP97922787A patent/EP0906576B1/de not_active Expired - Lifetime
- 1997-05-28 ES ES97922787T patent/ES2180052T3/es not_active Expired - Lifetime
- 1997-05-28 AT AT97922787T patent/ATE221996T1/de not_active IP Right Cessation
- 1997-05-28 AU AU28835/97A patent/AU2883597A/en not_active Abandoned
- 1997-05-28 DE DE69714591T patent/DE69714591T2/de not_active Expired - Fee Related
- 1997-05-28 CA CA002256310A patent/CA2256310A1/en not_active Abandoned
- 1997-05-28 WO PCT/CA1997/000368 patent/WO1997045744A1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10311248A1 (de) * | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
Also Published As
Publication number | Publication date |
---|---|
ATE221996T1 (de) | 2002-08-15 |
US5719032A (en) | 1998-02-17 |
EP0906576A1 (de) | 1999-04-07 |
ES2180052T3 (es) | 2003-02-01 |
AU2883597A (en) | 1998-01-05 |
DE69714591D1 (de) | 2002-09-12 |
EP0906576B1 (de) | 2002-08-07 |
WO1997045744A1 (en) | 1997-12-04 |
CA2256310A1 (en) | 1997-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO175944C (no) | Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse | |
Natali et al. | Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40 S to human melanoma cells | |
WO1997035021A3 (en) | Prostate specific antigen oligo-epitope peptide | |
DE69734109D1 (de) | Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung | |
TR200001253T2 (tr) | Tümöre özel antijenler | |
MX9704898A (es) | Anticuerpo anti-idiotipo monoclonal murino 3h1. | |
DE69714591D1 (de) | Prostatakrebs- spezifischer antikörper für immundetektion und immuntherapie | |
ATE168472T1 (de) | Nachweis von prostat-spezifischen antigen in brusttumoren | |
DE3789781D1 (de) | Antigene, Antikörper und Verfahren zur Identifizierung humaner metastatischer Tumoren und Zellinien zur Herstellung dieser Antikörper. | |
ES2101695T3 (es) | Haptoglobina relacionada con el cancer (hpr). | |
Ferrone et al. | A human high molecular weightmelanoma associated antigen (HMWW_MAA) defined by monoclonal antibodies: a useful marker to radioimage tumor lesions in patients with melanoma. Brookhaven National Laboratories. Associated Universities | |
DE59712259D1 (de) | E-Cadherin-Mutationen als Grundlage zur Diagnostik und Therapie humaner maligner Tumoren | |
DK0495910T3 (da) | Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer | |
DE68924983D1 (de) | Anti-idiotyp antikörper induktion eines antitumorenresponses. | |
ATE305140T1 (de) | Verfahren zur detektion der hk2 polypeptide | |
Hoon et al. | Current status of human melanoma vaccines: can they control malignant melanoma? | |
Herberman | Delayed hypersensitivity response toward autochthonous tumor extracts | |
DE59712247D1 (de) | Mammakarzinom-assoziiertes gen | |
Kehayov et al. | Demonstration of a phase (stage)‐specific embryonic brain antigen in human meningioma | |
Hersey et al. | The nature and significance of melanoma antigens recognized by human subjects | |
Catalona et al. | Immunology of genitourinary tumors | |
EP0278160A3 (de) | Menschliche monoklonale Antikörper gegen Krebs, Hybridoma-Zellinien, die sie herstellen und ihre Anwendungen | |
Kageshita et al. | Human high molecular weight‐melanoma associated antigen mimicry by mouse anti‐idiotypic MAb MK2‐23. Immunohistochemical analysis of the reactivity of anti‐anti‐idiotypic MAb with surgically removed melanoma lesions | |
MX9800821A (es) | Aislamiento y/o conservacion de celulas dentriticas para la inmunoterapia del cancer de la prostata. | |
ES8707796A1 (es) | Metodo para la cuantificacion del antigeno procoagulante delcancer en una muestra biologica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |